2020年12月23日，中银国际作为联席财务顾问协助创胜集团顺利完成1.05亿美元交叉轮融资。本轮融资由中国国有企业结构调整基金（国调基金）领投，碧桂园创投、卡塔尔投资局等多家知名机构作为新投资者参与投资。招商局资本、国调招商并购基金、礼来亚洲基金、腾跃基金、红杉资本中国基金等多位现有股东继续参投。

       在本次融资过程中，中银国际与创胜集团充分对接，在深入了解创胜集团的战略定位、商业模式和发展方向的基础上，从运营、投资及对接资本市场等多方面提供了建议，并凭借全球投资者网络，在引入关键投资者方面发挥了关键性作用，为创胜集团引进了多家大型海外投资者，进一步充实了创胜集团的研发和运营资本，充分体现了中银国际多元化金融服务及一体化联动机制的优势。

       创胜集团是一家具备生物制药研发、临床及工艺开发和生产全流程整合能力的国际化生物制药公司，开发管线涵盖肿瘤和经筛选的非肿瘤领域的十余个新药分子。创胜集团已搭建了全球业务布局：在中国苏州设有药物发现、转化研究和临床研究中心，在杭州拥有工艺与产品开发中心和药物生产基地，在北京、上海、广州和美国普林斯顿分别设有临床开发中心，并在美国波士顿设立了对外合作中心。

       中银国际是中国银行旗下的全资附属投资银行，为海内外客户提供包括企业融资、收购兼并、财务顾问、证券销售、定息收益、私人银行、资产管理、直接投资、股票衍生产品、杠杆及结构融资、环球大宗商品等在内的全方位投资银行服务，长期在香港新股发行、股票交易、债券发行、强积金等市场和中国内地资本市场保持领先地位。

       On December 23,2020, Transcenta Holding Limited (Transcenta) announced the completion of a 105 million USD crossover financing. BOCI acted as the joint financial advisor for this transaction. China Structural Reform Fund led the financing round, participated by new investors including Country Garden Venture Capital, Qatar Investment Authority, and other prominent institutional investors. Existing investors including CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, and Sequoia Capital China also participated in this round. With its global investor network, BOCI has brought in a number of large overseas investors to Transcenta, which further enriched Transcenta's R&D and operating capital.

       During this financing, BOCI fully connected with Transcenta. Based on the in-depth understanding of Transcenta’s strategic positioning, business model and development strategy, BOCI provided suggestions to Transcenta from various aspects such as operation, investment and capital connection. BOCI played a decisive role in the introduction of key investors, which fully demonstrated the advantages of BOCI's one-step internationalized financial services.

       Transcenta is an international biopharmaceutical company with the ability to integrate the entire process of biopharmaceutical R&D, clinical and process development and production. Transcenta's R&D pipeline covers more than ten new drug molecules in the tumor and non-tumor fields.Transcenta has established a global business network.It has a discovery, translational and clinical research center in Suzhou, a process and product development center and manufacturing facility in Hangzhou, and clinical development centers in Shanghai, Beijing and Princeton, and an external partnering center in Boston.

       BOCI is a wholly owned subsidiary of Bank of China, which provides one-step services including corporate financing, merger and acquisition, financial advisory, securities sales, fixed income, private banking, asset management, private equity, equity derivatives products, leveraged and structured financing, and global commodities. BOCI has long maintained a leading position in Hong Kong IPO, equity sales, bond issuance, MPF market and mainland China capital market.